SCAP RNAi Composition for Targeted NAFLD Lipid Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nonalcoholic fatty liver disease (NAFLD) are inadequate, with no pharmacologic therapies approved, and existing approaches focus on weight loss and secondary conditions rather than directly targeting the underlying lipid biosynthesis pathways mediated by the sterol regulatory element binding protein (SREBP) chaperone (SCAP).
Innovation Solution
Development of double-stranded ribonucleic acid (RNAi) agents that specifically target and inhibit the expression of the SCAP gene, utilizing sense and antisense strands with modified nucleotides and phosphorothioate linkages to form RNA-induced silencing complexes, thereby reducing lipid biosynthesis and addressing NAFLD progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RNAi agents are developed to target SCAP gene expression, then lipid biosynthesis is inhibited and NAFLD progression is halted, but treatment complexity and development challenges increase
Solution Approach 1:
The patent uses RNAi agents as intermediary molecules that mediate between the therapeutic goal (inhibiting lipid biosynthesis) and the target (SCAP gene). The small interfering RNA molecules serve as mediators that specifically bind to SCAP mRNA, triggering its degradation and thereby inhibiting SCAP protein production without directly interacting with the gene or protein
Solution Approach 2:
The patent replaces traditional pharmacological approaches (chemical drugs) with a biological mechanism (RNA interference). Instead of using small molecule drugs that chemically inhibit enzymes or receptors, the invention uses RNA molecules that exploit the cell's natural RNAi machinery to achieve gene silencing, substituting a mechanical/chemical system with a biological one
2Object-affected harmful factors
If SCAP expression is inhibited to reduce lipid accumulation, then liver fat accumulation is reduced, but cardiovascular health and cholesterol levels may be affected
Solution Approach 1:
The patent applies local quality by using liver-specific delivery mechanisms and liver-targeting ligands on the RNAi agents. This ensures that SCAP inhibition occurs primarily in hepatocytes (liver cells) rather than systemically, allowing selective reduction of liver fat accumulation while minimizing effects on other tissues and cardiovascular health
Solution Approach 2:
The patent changes the parameter of tissue specificity through modified delivery systems. By incorporating liver-targeting moieties and optimizing delivery vehicle properties, the invention shifts the effect from systemic SCAP inhibition to localized hepatic inhibition, thereby reducing harmful liver fat while preserving beneficial cholesterol metabolism in other tissues
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNAi agents effectively inhibit SCAP expression, potentially halting the progression of NAFLD by reducing lipid accumulation in liver cells, offering a therapeutic approach for conditions such as nonalcoholic steatohepatitis (NASH) and other SCAP-associated diseases.
Implementation Method 1
double stranded ribonucleic acid (RNAi) agents that specifically target and inhibit the expression of the SCAP gene, utilizing sense and antisense strands with modified nucleotides and phosphorothioate linkages to form RNA-induced silencing complexes
Data Source
AI summary
The invention relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting the SCAP gene, as well as methods of inhibiting expression of a SCAP gene and methods of treating subjects having a SCAP-associated disorder, such as nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), using such dsRNAi agents and compositions.